Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.

Kristine Peregrino Lacuna, Matthew Ingham, Martee L. Hensley et al.|Journal of Clinical Oncology|2023

Cited by 2